Petros Pharmaceuticals, Inc. (PTPI) stock
PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026Market cap $135.07KP/E –Yield –
Petros Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Petros Pharmaceuticals's R&D Expenses for the twelve months ending Dec 31, 2024 was $2.62M, up 8.5% year over year. For fiscal 2024 it was $2.62M, up 8.5% from the year before. The highest annual figure on record is $2.62M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.62M | +8.5% |
| FY2023 | Dec 31, 2023 | $2.41M | +38.4% |
| FY2022 | Dec 31, 2022 | $1.74M | -2.7% |
| FY2021 | Dec 31, 2021 | $1.79M | +289.1% |
| FY2020 | Dec 31, 2020 | $459.64K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $101.95K | -87.8% |
| Q3 FY2024 | Sep 30, 2024 | $588.36K | +51.2% |
| Q2 FY2024 | Jun 30, 2024 | $368.80K | -57.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.56M | +387.6% |
| Q4 FY2023 | Dec 31, 2023 | $834.33K | +369.4% |
| Q3 FY2023 | Sep 30, 2023 | $389.09K | -47.1% |
| Q2 FY2023 | Jun 30, 2023 | $866.58K | +105.7% |
| Q1 FY2023 | Mar 31, 2023 | $319.09K | -21.3% |
| Q4 FY2022 | Dec 31, 2022 | $177.76K | -64.5% |
| Q3 FY2022 | Sep 30, 2022 | $735.92K | +3736.7% |
| Q2 FY2022 | Jun 30, 2022 | $421.24K | +177.4% |
| Q1 FY2022 | Mar 31, 2022 | $405.36K | +1000.7% |
| Q2 FY2021 | Jun 30, 2021 | $500.05K | +280.0% |
| Q1 FY2021 | Mar 31, 2021 | $19.18K | -86.2% |
| Q4 FY2020 | Dec 31, 2020 | $151.84K | – |
| Q3 FY2020 | Sep 30, 2020 | $36.83K | – |
| Q2 FY2020 | Jun 30, 2020 | $131.58K | – |
| Q1 FY2020 | Mar 31, 2020 | $139.39K | – |
See a number that looks wrong?